Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal STAR-T Cell Injection in Patients With Multiple Sclerosis
NCT07523100Phase 1Not yet recruiting
- Sponsor
- Daishi Tian
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Universal STAR-T Cell Injection in multiple sclerosis (MS), sponsored by Daishi Tian. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events at 6 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Universal STAR-T Cell Injection
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07523100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523100.